Literature DB >> 11721766

Predicting the liver histology in chronic hepatitis C: how good is the clinician?

J Romagnuolo1, G S Jhangri, L D Jewell, V G Bain.   

Abstract

OBJECTIVE: Liver biopsy is believed to be necessary before antiviral treatment in hepatitis C. Studies have found symptoms and biochemistry poorly predictive of grade and stage. In practice, a combination of factors is used to anticipate histology. The aim of this study is to evaluate the ability of global clinical assessment to predict histology in hepatitis C.
METHODS: Fifty-four consecutive patients referred to a university center for consideration of antiviral therapy were enrolled. Clinical and laboratory data were recorded as was a prediction of the inflammatory grade (0-3) and fibrotic stage (0-3), with fibrotic stage 3 referring to cirrhosis. Liver biopsies were read by a blinded pathologist. The predictive value of the clinical assessment and individual parameters was assessed.
RESULTS: All predictions were < or = 1 point off the actual grade and stage. Thirty-six (66.7%) patients' grades and 41 (75.9%) patients' stages were exactly predicted. All four cirrhotic patients (sensitivity 100%, specificity 94%) and one case of hemochromatosis were correctly predicted. Spider nevi, organomegaly, white blood cell count < or = 4 x 10(9)/L, ALT > 120 U/L, bilirubin > 20 micromol/L, albumin < or = 35 g/L, and ferritin > 200 microg/L predicted grade > or =2. Stage > or =2 was associated with age > 40 yr, previous decompensation, spider nevi, organomegaly, white blood cell count < or = 4 x 10(9)/L, albumin < or = 35 g/L, platelets < or = 150 x 10(9)/L, and international normalized ratio > 1.2. Grade correlated with stage (Spearman coefficient = 0.54, p < 0.001). By multivariate analysis, ferritin plus spider nevi or hypoalbuminemia was independently predictive of inflammation. Spider nevi and thrombocytopenia, with either splenomegaly or hypoalbuminemia, were useful three-variable models for predicting fibrosis. The corresponding scoring systems produced useful likelihood ratios.
CONCLUSIONS: Global clinical assessment mirroring clinical practice in a tertiary liver transplant center is moderately accurate in predicting grade and stage in hepatitis C. Liver biopsy is the current gold standard; however, the amount of new information gleaned is less than was perceived. The need for routine biopsy before antiviral treatment in hepatitis C should be reevaluated in a multicenter study.

Entities:  

Mesh:

Year:  2001        PMID: 11721766     DOI: 10.1111/j.1572-0241.2001.05275.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  5 in total

1.  Usefulness of a liver biopsy in the evaluation of patients with elevated ALT values and serological markers of hepatitis viral infection: an AIGO study.

Authors:  A Andriulli; V Festa; G Leandro; M Rizzetto
Journal:  Dig Dis Sci       Date:  2001-07       Impact factor: 3.199

2.  Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B.

Authors:  Ping Liu; Yi-Yang Hu; Cheng Liu; Da-Yuan Zhu; Hui-Ming Xue; Zhi-Qiang Xu; Lie-Ming Xu; Cheng-Hai Liu; Hong-Tu Gu; Zhi-Qing Zhang
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

3.  The combined elevation of tumor markers CA 19-9 and CA 125 in liver disease patients is highly specific for severe liver fibrosis.

Authors:  Maximilian Schöniger-Hekele; Christian Müller
Journal:  Dig Dis Sci       Date:  2006-02       Impact factor: 3.199

Review 4.  Thrombocytopenia in Patients with Chronic Hepatitis C Virus Infection.

Authors:  Sumit Dahal; Smrity Upadhyay; Rashmi Banjade; Prajwal Dhakal; Nabin Khanal; Vijaya Raj Bhatt
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-03-01       Impact factor: 2.576

5.  Impact of spider nevus and subcutaneous collateral vessel of chest/abdominal wall on outcomes of liver cirrhosis.

Authors:  Hongyu Li; Ran Wang; Nahum Méndez-Sánchez; Ying Peng; Xiaozhong Guo; Xingshun Qi
Journal:  Arch Med Sci       Date:  2018-03-28       Impact factor: 3.318

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.